Coherus BioSciences Analyst Ratings

Benzinga ·  11/29/2023 01:55

What is the target price for Coherus BioSciences (CHRS)?The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by Truist Securities on November 28, 2023. The analyst firm set a price target for $12.00 expecting CHRS to rise to within 12 months (a possible 501.50% upside). 22 analyst firms have reported ratings in the last year.What is the most recent analyst rating for Coherus BioSciences (CHRS)?The latest analyst rating for Coherus BioSciences (NASDAQ: CHRS) was provided by Truist Securities, and Coherus BioSciences reiterated their buy rating.When is the next analyst rating going to be posted or updated for Coherus BioSciences (CHRS

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment